2-[(cyclopropylmethyl)(propyl)amino]-6-[methyl(methylsulfonyl)amino]isonicotinic acid | 860312-88-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[(cyclopropylmethyl)(propyl)amino]-6-[methyl(methylsulfonyl)amino]isonicotinic acid
• 英文别名: 2-[Cyclopropylmethyl(propyl)amino]-6-[methyl(methylsulfonyl)amino]pyridine-4-carboxylic acid
• CAS: 860312-88-5
• 化学式: C₁₅H₂₃N₃O₄S
• 分子量: 341.431
• InChiKey: ISNZBDBYSKJLFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  99.2
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
  申请人：Barrow C. James

  公开号：US20070142634A1

  公开（公告）日：2007-06-21

  The present invention is directed to phenylamide and pyridylamide derivative compounds of which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及苯胺和吡啶胺衍生物化合物，这些化合物是β-分泌酶的抑制剂，并且在治疗涉及β-分泌酶的疾病，如阿尔茨海默病中有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗涉及β-分泌酶的这类疾病中使用这些化合物和组合物。
• [EN] PYRROLO[DÉRIVÉS DE PYRROLO[20091015WO2007140222A2NOVARTIS AG [CH], et al20071206513-311,18X1-14XWO03074530A1HOFFMANN LA ROCHE [CH]20030912387-151Y1-14YWO2005107760A1IRM LLC [US], et al20051117311Y1-14YUS7319102B1CLARK MICHAEL PHILIP [US], et al200801153396444930-36Y1-14YWO2007140222A2NOVARTIS AG [CH], et al20071206WO03074530A1HOFFMANN LA ROCHE [CH]20030912WO2005107760A1IRM LLC [US], et al20051117US7319102B1CLARK MICHAEL PHILIP [US], et al20080115<br/>[FR] DÉRIVÉS DE PYRROLO[20091015WO2007140222A2NOVARTIS AG [CH], et al20071206513-311,18X1-14XWO03074530A1HOFFMANN LA ROCHE [CH]20030912387-151Y1-14YWO2005107760A1IRM LLC [US], et al20051117311Y1-14YUS7319102B1CLARK MICHAEL PHILIP [US], et al200801153396444930-36Y1-14YWO2007140222A2NOVARTIS AG [CH], et al20071206WO03074530A1HOFFMANN LA ROCHE [CH]20030912WO2005107760A1IRM LLC [US], et al20051117US7319102B1CLARK MICHAEL PHILIP [US], et al20080115
  申请人：ORGANON NV

  公开号：WO2009124965A1

  公开（公告）日：2009-10-15

  The present invention relates to a pyrrolo[2,3-d]pyrimidin-2-yl-amine derivative according to formula (I) wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said pyrrolo[2,3-d]pyrimidine-2-ylamine derivatives and to their use in therapy, for instance in the treatment of PKCθ mediated disorders.

  本发明涉及一种根据式(I)定义的吡咯并[2,3-d]嘧啶-2-基胺衍生物，其中变量如规范中所定义，或其药学上可接受的盐或溶剂，本发明还涉及一种含有一种或多种所述吡咯并[2,3-d]嘧啶-2-基胺衍生物的药物组合物，以及它们在治疗中的使用，例如在治疗PKCθ介导的疾病中。
• PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1697308B1

  公开（公告）日：2014-03-19
• US7550481B2
  申请人：——

  公开号：US7550481B2

  公开（公告）日：2009-06-23